US FDA announces major recall of over 67,000 cases of Power Stick deodorant
The FDA and A.P. Deauville issued a voluntary recall of over 67,000 cases of Power Stick deodorant last week that were sold across the country. The recall notice didn't specify the exact nature of issue that has taken place in the deodorant but stated that it is related to deviations with 'current good manufacturing practices' (cGMP).
The recall was issued on July 10 and includes over 21,200 cases of the brand's 'power fresh'-scented Power Stick for Her Roll-On Antiperspirant Deodorant, over 22,400 cases of its 'spring fresh' scented Power Stick Invisible Protection Roll-On Antiperspirant Deodorant and over 23,400 cases of Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant.
The Easton, Pennsylvania based company has not issued a statement regarding the recall of its products. A report by The Independent stated that the deodorant was available for purchase on Walmart for a pack of three for $21, and a pack of 24 deodorants was available on Dollar Tree for $30. E-commerce giant Amazon was also selling the product.
The affected lot numbers for Power Stick for her roll-on Antiperspirant Deodorant are:
032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341, 082826E402
The lot numbers for the affected Power Stick Invisible Protection Roll-On Antiperspirant Deodorant are:
031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391, 111626G231
And the affected lot numbers for Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant are:
101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091, 111626G221.
Among the other SKUs in the personal care category, A.P. Deauville manufactures shampoos, conditioners, lotions, body washes, and facial wipes.
(with inputs from The Independent)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
6 hours ago
- The Hindu
US may revise hormone replacement therapy warnings
US Food and Drug Administration Commissioner Marty Makary signaled Thursday that he is open to revising strict warning labels on Hormone Replacement Therapy, following testimony from experts who said the treatment's risks have long been exaggerated. HRT is taken to replace estrogen the body stops producing after menopause -- when periods end permanently -- and helps relieve symptoms such as hot flashes, vaginal discomfort, and pain during sex. But its use has plummeted in recent years amid concerns including a possible link to invasive breast cancer. Food and Drug Administration (FDA) chief Marty Makary, who convened Thursday's meeting of outside experts, told AFP: "We have to revisit these topics." He argued that the framework that led to so-called "black box warnings" -- the strongest warning the FDA can require for prescription drugs -- "came from a different era." "Not only is there no clinical trial showing an increase in breast cancer mortality, but there are also other tremendous long term health benefits," Makary added. The 12 experts convened by the agency said HRT's benefits go beyond easing menopausal symptoms. They cited evidence for reduced fracture risk, improved cardiovascular and cognitive health, and fewer urinary tract infections. "Estrogen is the only well-established intervention to reduce the frequency of osteoporotic fracture in postmenopausal women, to the tune of 30 to 50 percent," said Vonda Wright, an orthopedic surgeon at the University of Central Florida. Roberta Diaz Brinton, director of the Center for Innovation in Brain Science, said her research suggests the reason two-thirds of people globally with Alzheimer's are women is not because they live slightly longer than men, but because the disease begins during the menopausal transition. "Depending upon when hormone therapy is introduced... there's a significant reduction in risk of developing Alzheimer's disease," she said. The University of Arizona researcher linked menopause to a drop in the brain's ability to metabolize glucose and a rise in protein plaque deposits. Panelists blamed the collapse in HRT use on the Women's Health Initiative (WHI), a landmark clinical trial halted in 2002 after flagging a possible increased breast cancer risk -- findings they say were misinterpreted. "Prescriptions for hormone replacement therapy plummeted in the United States, women flushed their pills down the toilet," Makary said in his opening remarks, mentioning his own mother's experience of multiple bone fractures in old age. Critics of the WHI argue it included participants well past menopause -- when risks are higher and benefits lower -- and used outdated formulations no longer common today. Label changes Still, the issue remains divisive within the medical community. HRT can be administered through various means including orally, through skin patches, or vaginally; and is given either as estrogen alone or with progesterone. The FDA's own warning label for it cites risks including endometrial cancer, breast cancer, and life-threatening blood clots. Adriane Fugh-Berman, who directs a project that promotes rational prescribing at Georgetown University, attended as an observer and criticised the lack of dissenting voices. "This was a very one-sided panel of people who are all proponents of hormone therapy and who seem to have a very poor understanding of the evidence," she told AFP. "While hormones can be a useful treatment for severe menopausal symptoms, they should not be used for chronic disease prevention," she added, noting that no randomised clinical trial -- the gold standard of evidence -- has found HRT beneficial for cognition or dementia prevention. She also said that after the WHI findings were released, hormone use fell globally -- and breast cancer rates dropped across registries tracking them. Several of the panelists had ties to companies offering menopause treatments or are affiliated with the advocacy group "Let's Talk Menopause," which receives pharmaceutical funding and campaigns to revise FDA warning labels.
Time of India
11 hours ago
- Time of India
National Ice Cream Day 2025: FDA issues risk warning due to 'class II health risk'. Here's what you can do
It's the National Ice Cream Day in the United States and from ice cream chains to restaurants and even grocery stores, there are ways to score freebies and deals all day long. However, on this 'sweet' day, an Ohio creamery has recalled several of its ice cream flavors because of undeclared allergens , reports NewsWeek. Based in Wauseon, Turkeyfoot Creek Creamery has issued a voluntary recall for multiple pint-size products that were distributed to six retail locations. The affected items have been pulled from store shelves. Explore courses from Top Institutes in Select a Course Category others healthcare Finance MCA Management Technology Data Science Others Cybersecurity Artificial Intelligence Public Policy CXO MBA Healthcare Digital Marketing Project Management Design Thinking PGDM Data Science Leadership Degree Operations Management Data Analytics Product Management Skills you'll gain: Duration: 16 Weeks Indian School of Business CERT - ISB Cybersecurity for Leaders Program India Starts on undefined Get Details The FDA has classified the recall as 'Class II health risk'- which refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas Prices In Dubai Might Be More Affordable Than You Think Villas In Dubai | Search Ads Get Quote Undo ALSO READ: Barack Obama-Michelle finally address divorce rumours: 'There hasn't been one moment in our marriage...' Ohio creamery recalls ice cream flavours Millions of people in US are subject to food allergies or food sensitivities, says FDA. Food sensitivities can range from mild reactions to potentially life-threatening symptoms. The agency recognizes nine major food allergens: milk, eggs, sesame, fish, tree nuts, crustacean shellfish, peanuts, wheat and soybeans. Live Events The recall issued by Ohio creamery affects pints of Mocha, Cacao, Cookie Dough, Cookies and Cream, Cacao Brownie Bites, Chocolate Peanut Butter and Avalanche as they may contain "undeclared soy and/or wheat", reports NewsWeek. ALSO READ: Astronomer CEO Andy Byron's divorce bill revealed following Coldplay kiss cam controversy with HR chief While no illnesses have been reported so far, the presence of undeclared allergens poses a potential risk to consumers with soy or wheat allergies. Soy can trigger reactions ranging from mild symptoms—such as hives and stomach cramps—to severe anaphylaxis in sensitive individuals. Wheat allergies can cause similar symptoms—including respiratory issues, skin reactions and, in some cases, life-threatening allergic responses. The recalled ice cream pints were sold in paper cartons with paper lids and distributed to six retailers in Indiana, Michigan, and Ohio. The recall covers all expiration dates, which are printed on the bottom of each carton. "There have been no reports of illness involving products addressed in this recall, however, individuals exhibiting signs or symptoms of an allergic reaction after consuming Turkeyfoot Creek Creamery Ice Cream involved in this recall should contact a physician immediately," according to a news release from the Ohio Department of Agriculture. Consumers who have purchased the affected products are urged not to consume them and to return them to the place of purchase for a full refund. Those with questions can call 419-583-7124.
Time of India
18 hours ago
- Time of India
Deodorant recalled: Why FDA recalled 67,000 cases of Power Stick deodorants sold at Walmart, Dollar Tree, and Amazon
After blueberries, Greek yogurt, chocolates, and even water bottles, the FDA is now recalling deodorants! The Food and Drug Administration (FDA) has issued a voluntary recall of over 67,000 cases of Power Stick roll‑on deodorants manufactured by A.P. Deauville. The recall, which was announced on July 10, covers three popular variants – Power Stick for Her 'Power Fresh', Invisible Protection 'Spring Fresh', and Original Nourishing Invisible Protection. These products were sold widely through Walmart, Dollar Tree, and Amazon, affecting consumers across the United States. The recall was reportedly triggered by deviations from the FDA's Current Good Manufacturing Practices (cGMP), a red flag for production oversight and quality control, although no contamination was reported. Read on to know more. What caused the recall? On July 10, A.P. Deauville initiated the recall of 67,214 combined cases of Power Stick deodorant sold nationwide. For the recall, the FDA enforcement reported cGMP deviations, which listed failures in adhering to current good manufacturing practices as the primary reason. The FDA strictly enforces cGMP regulations to ensure products are consistently produced with accurate ingredients, proper strength, and no contamination. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Do you have a mouse? Desert Order Undo These regulations ensure that products are consistently manufactured in controlled environments, maintaining quality, safety, and efficacy. However, it is important to note that no harmful substance was found in those products. cGMP issues, although do not always indicate direct harm, any breach in manufacturing protocols – be it equipment calibration, hygiene, ingredient verification, or documentation control – can compromise product integrity, making this recall a critical decision. Why cGMP compliance matters Current Good Manufacturing Practices (cGMP) form a regulatory backbone ensuring that mass‑produced items, from medications to deodorants, meet rigorous safety and quality benchmarks. When deviations occur, whether in cleanliness, equipment calibration, or ingredient testing, consumer safety can't be guaranteed, even if no immediate harm is reported. Even in the absence of direct harm, any cGMP lapse poses potential quality risks, hence the proactive recall. Which items were recalled The recall includes three 1.8-oz roll‑on deodorants, each with specific lot numbers: Power Stick for Her Roll‑On 'Power Fresh' – 21,265 cases, e.g., lots 032026B011, 071226D381, 082826E402. Power Stick Invisible Protection 'Spring Fresh' Roll‑On – 22,482 cases, e.g., 031726A991, 071026D361, 111626G231. Power Stick Original Nourishing Invisible Protection – 23,467 cases, e.g., 032826B221, 070626D301, 111626G221. These Power Stick variants were sold nationwide via: Walmart – 3‑packs sold at around $21 Dollar Tree – 24‑packs for about $30 Amazon – available as individual or multi‑packs Consumers who purchased from any of these retailers are urged to inspect the UPC/barcode on the packaging, match the lot numbers printed beneath to see if their purchase is affected, and discontinue use if their deodorant is part of the recall.
